Enzon drops spinout plan

Enzon (NASDAQ:ENZN) discontinued its previously announced plan to spin off its biotechnology business into a separate public company, citing market conditions. In May, Enzon said it would spin out a biotech company to focus on developing cancer therapeutics using its PEGylation and Locked Nucleic Acid technologies (See BioCentury Extra, Wednesday, May 07, 2008). ...